pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Padcev
drug · antibody drug conjugate
save

enfortumab vedotin

Marketedupdated 6mo ago
by Astellas Pharma Inc🔗 ChEMBL
Approved
community read0 votes

🐶 often sniffed alongside

top 2
  • drugPADCEV48 co-mentions · 12 sources
  • tagApproval48 co-mentions · 12 sources

Antibody drug conjugate drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 6 investigational indications.

targets

Nectin-4Tubulin

all catalysts(12)

approval · 12
Dec 18, 2019
approval
7y ago
PADCEV (ENFORTUMAB VEDOTIN-EJFV) — FDA approval
enfortumab vedotin
→
Mar 22, 2021
approval
6y ago
PADCEV (ENFORTUMAB VEDOTIN-EJFV) — FDA approval
enfortumab vedotin
→
Jul 9, 2021
approval
5y ago
PADCEV (ENFORTUMAB VEDOTIN-EJFV) — FDA approval
enfortumab vedotin
→
Jul 9, 2021
approval
5y ago
PADCEV (ENFORTUMAB VEDOTIN-EJFV) — FDA approval
enfortumab vedotin
→
Oct 28, 2022
approval
4y ago
PADCEV (ENFORTUMAB VEDOTIN-EJFV) — FDA approval
enfortumab vedotin
→
Apr 3, 2023
approval
4y ago
PADCEV (ENFORTUMAB VEDOTIN-EJFV) — FDA approval
enfortumab vedotin
→
Apr 3, 2023
approval
4y ago
PADCEV (ENFORTUMAB VEDOTIN-EJFV) — FDA approval
enfortumab vedotin
→
Apr 18, 2023
approval
4y ago
PADCEV (ENFORTUMAB VEDOTIN-EJFV) — FDA approval
enfortumab vedotin
→
Dec 15, 2023
approval
3y ago
PADCEV (ENFORTUMAB VEDOTIN-EJFV) — FDA approval
enfortumab vedotin
→
Dec 15, 2023
approval
3y ago
PADCEV (ENFORTUMAB VEDOTIN-EJFV) — FDA approval
enfortumab vedotin
→
Feb 27, 2025
approval
2y ago
PADCEV (ENFORTUMAB VEDOTIN-EJFV) — FDA approval
enfortumab vedotin
→
Nov 21, 2025
approval
12mo ago
PADCEV (ENFORTUMAB VEDOTIN-EJFV) — FDA approval
enfortumab vedotin
→
view all 12 catalysts →

Trials studying enfortumab vedotin

  • phase3Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)recruitingn=390
  • phase2Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancerrecruitingn=27
  • phase2A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladderrecruitingn=240
  • phase2Study of EV for Recurrent Endometrial Carcinomarecruitingn=12
  • phase2Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancerrecruitingn=132
  • phase2A Study to Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and Programmed Cell Death Protein-1 ( PD 1) / (Programmed Death Ligand-1 (PD-L1) Inhibitor Therapycompletedn=40
  • phase2PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patientsactive not recruitingn=60
  • phase2Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancerrecruitingn=23

News(10)

  • Pfizer snags $1.5B financing from PE firm Blackstone to support Metsera asset
    With 10 active or planned Phase 3 trials underway for Metsera’s berobenatide, Pfizer has signed a deal with Blackstone Life Sciences to finance the program to approval.
    biospace · 4d ago
  • Pfizer flat in Q3 despite 32% growth for new and acquired products
    Sales of assets from Seagen and Biohaven grew in the third quarter, but it wasn’t enough for Pfizer to overcome declines across the Prevnar and COVID franchises.
    biospace · 13d ago
  • Drugmakers rush to pair up with Summit’s ivonescimab ahead of key verdict
    With companies including AstraZeneca, Pfizer and Revolution Medicines clamoring to get in on Summit Therapeutics’ Akeso-partnered PD-1xVEGF antibody, one analyst calls the asset “the next major bac…
    biospace · 15d ago
  • #ESMO26: AstraZeneca eyes Keytruda's Padcev spot; Lilly's ADC takes on Elahere; Nubeqa targets earlier prostate cancer
    MADRID — It's been estimated that almost 40,000 delegates will be attending this year's ESMO congress over five days in Madrid. And on Saturday, they have new data to review from AstraZeneca, Eli L…
    endpoints · 23d ago
  • Context scraps bispecific T-cell engager program to extend cash runway deeper into 2027
    Context Therapeutics has stopped development of the bispecific T-cell engager CT-95, freeing up cash to extend its runway beyond readouts on its two priority clinical programs.
    fiercebiotech · 3mo ago
  • Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch
    Some analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.
    biopharma_dive · 3mo ago
  • Pfizer cuts $2.5B more across R&D, manufacturing in ongoing restructure
    The additional cuts, which will primarily occur between 2027 and 2029, will cost some $6 billion as the pharma tries to ride out a post-COVID headache while facing stiff patent headwinds for major…
    biospace · 3mo ago
  • ‘We’ve been looking for a novel approach’: Why Novartis CEO ended ADC holdout for $1.5B Myricx deal
    For years, as Big Pharma poured billions into ADCs, Novartis CEO Vas Narasimhan notably stayed on the sidelines. Asked by Fierce during Novartis’ Q2 earnings call, Narasimhan explained why he is en…
    fiercebiotech · 3mo ago
  • Agenus surges on study pivot; Apnimed lines up an IPO
    Agenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA decision date.
    biopharma_dive · 4mo ago
  • Tris Pharma's CRL for narcolepsy drug; Agenus abandons Phase 3 CRC trial
    Plus, news about Insilico, Ipsen, Q32 Bio, GSK’s Jemperli, Drug Farm and Padcev. ❌ FDA rejects Tris Pharma’s narcolepsy drug: Its rejection letter said that “additional information will be necessar…
    endpoints · 4mo ago
view all news mentions →
brand
Padcev
trade names
Padcev
generic
enfortumab vedotin-ejfv
MOA
Nectin-4 binding agent; Tubulin inhibitor
indication
Muscle Invasive Bladder Cancer (MIBC)
phase
marketed
Data sources
openFDA · ClinicalTrials.gov · OpenTargets
last refreshed 5h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?